Download PDF
Semin Thromb Hemost 2017; 43(03): 291-299
DOI: 10.1055/s-0036-1593414
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Managing the Precarious Hemostatic Balance during Extracorporeal Life Support: Implications for Coagulation Laboratories

Anne M. Winkler
1   Director of Medical Affairs, Instrumentation Laboratory, Bedford, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
06 February 2017 (online)

    Permissions and Reprints

Abstract

For the past four decades, extracorporeal life support (ECLS) has been used to treat critically ill adult and pediatric patients with cardiac and/or respiratory failure unresponsive to medical management, and there are increasing numbers of centers performing ECLS for numerous indications worldwide. Despite the progress with advancing technology, hemorrhagic and thrombotic complications occur frequently and are associated with worse outcomes, but the exact cause is often elusive or multifactorial. As a result of the interaction between blood and a nonendothelialized circuit, there is activation of coagulation, fibrinolysis, as well as an increased inflammatory response; thus, anticoagulation of the patient and circuit is necessary. While unfractionated heparin (UFH) remains the mainstay anticoagulant used during ECLS, there is a paucity of published data to develop a universal anticoagulation guideline and centers are forced to create individualized protocols to guide anticoagulation management, frequently while lacking expertise. From an international survey, centers often use a combination of tests to guide management, which in turn can lead to discordant results and confused management. Studies are urgently needed to investigate optimization of current anticoagulation strategies with UFH, as well as use of alternative anticoagulants and nonthrombogenic biomaterials.

Keywords

extracorporeal life support - extracorporeal membrane oxygenation - anticoagulation - heparin monitoring
 

  • References

  • 1 Butt W, Heard M, Peek GJ. Clinical management of the extracorporeal membrane oxygenation circuit. Pediatr Crit Care Med 2013; 14 (5) (Suppl. 01) S13-S19
    CrossrefPubMedGoogle Scholar
  • 2 Gray BW, Haft JW, Hirsch JC, Annich GM, Hirschl RB, Bartlett RH. Extracorporeal life support: experience with 2,000 patients. ASAIO J 2015; 61 (1) 2-7
    CrossrefPubMedGoogle Scholar
  • 3 UK Collaborative ECMO Trail Group. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996; 348 (9020): 75-82
    CrossrefPubMedGoogle Scholar
  • 4 Bartlett RH, Roloff DW, Cornell RG, Andrews AF, Dillon PW, Zwischenberger JB. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics 1985; 76 (4) 479-487
    PubMedGoogle Scholar
  • 5 Peek GJ, Mugford M, Tiruvoipati R , et al; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009; 374 (9698): 1351-1363
    CrossrefPubMedGoogle Scholar
  • 6 ECLS Registry Report International Summary. January 2016. Available at: https://www.elso.org/Portals/0/Files/PDF/International%20Summary%20January%202016%20FIRST%20PAGE.pdf . Accessed December 15, 2016
    PubMedGoogle Scholar
  • 7 Murphy DA, Hockings LE, Andrews RK , et al. Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev 2015; 29 (2) 90-101
    CrossrefPubMedGoogle Scholar
  • 8 Annich GM. Extracorporeal life support: the precarious balance of hemostasis. J Thromb Haemost 2015; 13 (1) (Suppl. 01) S336-S342
    CrossrefPubMedGoogle Scholar
  • 9 Urlesberger B, Zobel G, Zenz W , et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996; 129 (2) 264-268
    CrossrefPubMedGoogle Scholar
  • 10 Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001; 27 (8) 1395-1400
    CrossrefPubMedGoogle Scholar
  • 11 McManus ML, Kevy SV, Bower LK, Hickey PR. Coagulation factor deficiencies during initiation of extracorporeal membrane oxygenation. J Pediatr 1995; 126 (6) 900-904
    CrossrefPubMedGoogle Scholar
  • 12 Zavadil DP, Stammers AH, Willett LD, Deptula JJ, Christensen KA, Sydzyik RT. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). J Extra Corpor Technol 1998; 30 (2) 83-90
    PubMedGoogle Scholar
  • 13 Hundalani SG, Nguyen KT, Soundar E , et al. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation. Pediatr Crit Care Med 2014; 15 (5) e198-e205
    CrossrefPubMedGoogle Scholar
  • 14 Peek GJ, Firmin RK. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45 (4) 250-263
    CrossrefPubMedGoogle Scholar
  • 15 Malfertheiner MV, Philipp A, Lubnow M , et al. Hemostatic changes during extracorporeal membrane oxygenation: a prospective randomized clinical trial comparing three different extracorporeal membrane oxygenation systems. Crit Care Med 2016; 44 (4) 747-754
    CrossrefPubMedGoogle Scholar
  • 16 Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004; 25 (26) 5681-5703
    CrossrefPubMedGoogle Scholar
  • 17 Da Q, Teruya M, Guchhait P, Teruya J, Olson JS, Cruz MA. Free hemoglobin increases von Willebrand factor-mediated platelet adhesion in vitro: implications for circulatory devices. Blood 2015; 126 (20) 2338-2341
    CrossrefPubMedGoogle Scholar
  • 18 Robinson TM, Kickler TS, Walker LK, Ness P, Bell W. Effect of extracorporeal membrane oxygenation on platelets in newborns. Crit Care Med 1993; 21 (7) 1029-1034
    CrossrefPubMedGoogle Scholar
  • 19 Nair P, Hoechter DJ, Buscher H , et al. Prospective observational study of hemostatic alterations during adult extracorporeal membrane oxygenation (ECMO) using point-of-care thromboelastometry and platelet aggregometry. J Cardiothorac Vasc Anesth 2015; 29 (2) 288-296
    CrossrefPubMedGoogle Scholar
  • 20 Cheung PY, Sawicki G, Salas E, Etches PC, Schulz R, Radomski MW. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates. Crit Care Med 2000; 28 (7) 2584-2590
    CrossrefPubMedGoogle Scholar
  • 21 Mutlak H, Reyher C, Meybohm P , et al. Multiple electrode aggregometry for the assessment of acquired platelet dysfunctions during extracorporeal circulation. Thorac Cardiovasc Surg 2015; 63 (1) 21-27
    PubMedGoogle Scholar
  • 22 Saini A, Hartman ME, Gage BF , et al. Incidence of platelet dysfunction by thromboelastography-platelet mapping in children supported with ECMO: a pilot retrospective study. Front Pediatr 2015; 3 (116) 116
    PubMedGoogle Scholar
  • 23 Heilmann C, Geisen U, Beyersdorf F , et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2012; 38 (1) 62-68
    CrossrefPubMedGoogle Scholar
  • 24 Kalbhenn J, Schmidt R, Nakamura L, Schelling J, Rosenfelder S, Zieger B. Early diagnosis of acquired von Willebrand syndrome (AVWS) is elementary for clinical practice in patients treated with ECMO therapy. J Atheroscler Thromb 2015; 22 (3) 265-271
    CrossrefPubMedGoogle Scholar
  • 25 Ranucci M, Baryshnikova E, Isgrò G , et al. Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients. Crit Care 2014; 18 (5) 504
    CrossrefPubMedGoogle Scholar
  • 26 Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14 (2) e77-e84
    CrossrefPubMedGoogle Scholar
  • 27 Nankervis CA, Preston TJ, Dysart KC , et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J 2007; 53 (1) 111-114
    CrossrefPubMedGoogle Scholar
  • 28 Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO. Am J Clin Pathol 2010; 134 (6) 950-954
    CrossrefPubMedGoogle Scholar
  • 29 Liveris A, Bello RA, Friedmann P , et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med 2014; 15 (2) e72-e79
    CrossrefPubMedGoogle Scholar
  • 30 Alexander DC, Butt WW, Best JD, Donath SM, Monagle PT, Shekerdemian LS. Correlation of thromboelastography with standard tests of anticoagulation in paediatric patients receiving extracorporeal life support. Thromb Res 2010; 125 (5) 387-392
    CrossrefPubMedGoogle Scholar
  • 31 Bembea MM, Schwartz JM, Shah N , et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013; 59 (1) 63-68
    CrossrefPubMedGoogle Scholar
  • 32 Kessel AD, Kline M, Zinger M, McLaughlin D, Silver P, Sweberg TM. The impact and statistical analysis of a multifaceted anticoagulation strategy in children supported on ECMO: performance and pitfalls. J Intensive Care Med 2017; 32 (1) 59-67
    CrossrefPubMedGoogle Scholar
  • 33 Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006; 96 (5) 547-552
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196 (5) 436-440
    CrossrefPubMedGoogle Scholar
  • 35 Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69 (5) 685-689
    CrossrefPubMedGoogle Scholar
  • 36 Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69 (5) 674-684
    CrossrefPubMedGoogle Scholar
  • 37 Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975; 43 (3) 346-353
    CrossrefPubMedGoogle Scholar
  • 38 Green TP, Isham-Schopf B, Steinhorn RH, Smith C, Irmiter RJ. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Crit Care Med 1990; 18 (5) 494-498
    CrossrefPubMedGoogle Scholar
  • 39 Perry DJ, Fitzmaurice DA, Kitchen S, Mackie IJ, Mallett S. Point-of-care testing in haemostasis. Br J Haematol 2010; 150 (5) 501-514
    CrossrefPubMedGoogle Scholar
  • 40 Ojito JW, Hannan RL, Burgos MM , et al. Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution. J Extra Corpor Technol 2012; 44 (1) 15-20
    PubMedGoogle Scholar
  • 41 Fries D, Streif W. Point-of-care testing in critically ill patients. Semin Thromb Hemost 2015; 41 (1) 75-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Atallah S, Liebl M, Fitousis K, Bostan F, Masud F. Evaluation of the activated clotting time and activated partial thromboplastin time for the monitoring of heparin in adult extracorporeal membrane oxygenation patients. Perfusion 2014; 29 (5) 456-461
    CrossrefPubMedGoogle Scholar
  • 43 Rapaport SI, Vermylen J, Hoylaerts M , et al. The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost 2004; 2 (12) 2250-2259
    CrossrefPubMedGoogle Scholar
  • 44 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287 (7) 324-327
    CrossrefPubMedGoogle Scholar
  • 45 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49 (2) 171-184
    CrossrefPubMedGoogle Scholar
  • 46 Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49 (1) 10-14
    CrossrefPubMedGoogle Scholar
  • 47 Schouwers SM, Delanghe JR, Devreese KM. Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?. Thromb Res 2010; 125 (1) 102-104
    CrossrefPubMedGoogle Scholar
  • 48 Denson KW, Bonnar J. The measurement of heparin. A method based on the potentiation of anti-factor Xa. Thromb Diath Haemorrh 1973; 30 (3) 471-479
    PubMedGoogle Scholar
  • 49 Kostousov V, Nguyen K, Hundalani SG, Teruya J. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med 2014; 138 (11) 1503-1506
    CrossrefPubMedGoogle Scholar
  • 50 Baird CW, Zurakowski D, Robinson B , et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007; 83 (3) 912-919 , discussion 919–920
    CrossrefPubMedGoogle Scholar
  • 51 Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med 2012; 13 (6) e363-e371
    CrossrefPubMedGoogle Scholar
  • 52 Northrop MS, Sidonio RF, Phillips SE , et al. The use of an extracorporeal membrane oxygenation anticoagulation laboratory protocol is associated with decreased blood product use, decreased hemorrhagic complications, and increased circuit life. Pediatr Crit Care Med 2015; 16 (1) 66-74
    CrossrefPubMedGoogle Scholar
  • 53 O'Meara LC, Alten JA, Goldberg KG , et al. Anti-Xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. ASAIO J 2015; 61 (3) 339-344
    CrossrefPubMedGoogle Scholar
  • 54 Irby K, Swearingen C, Byrnes J, Bryant J, Prodhan P, Fiser R. Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit/membrane oxygenator change: a retrospective pediatric study. Pediatr Crit Care Med 2014; 15 (4) e175-e182
    CrossrefPubMedGoogle Scholar
  • 55 Lequier LAG, Al-Ibraham O, Bembea M , et al. ELSO Anticoagulation Guideline. 2014. Available at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf . Accessed April 20, 2016
    PubMedGoogle Scholar
  • 56 Prakash S, Wiersema UF, Bihari S, Roxby D. Discordance between ROTEM® clotting time and conventional tests during unfractionated heparin-based anticoagulation in intensive care patients on extracorporeal membrane oxygenation. Anaesth Intensive Care 2016; 44 (1) 85-92
    PubMedGoogle Scholar
  • 57 Phillips MR, Khoury AI, Ashton RF, Cairns BA, Charles AG. The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution. Anaesth Intensive Care 2014; 42 (1) 97-98
    PubMedGoogle Scholar
  • 58 Scott LK, Grier LR, Conrad SA. Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporeal support and treated with argatroban. Pediatr Crit Care Med 2006; 7 (3) 255-257
    CrossrefPubMedGoogle Scholar
  • 59 Beiderlinden M, Treschan T, Görlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007; 31 (6) 461-465
    CrossrefPubMedGoogle Scholar
  • 60 Pieri M, Agracheva N, Bonaveglio E , et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013; 27 (1) 30-34
    CrossrefPubMedGoogle Scholar
  • 61 Nagle EL, Dager WE, Duby JJ , et al. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med 2013; 14 (4) e182-e188
    CrossrefPubMedGoogle Scholar
  • 62 Jyoti A, Maheshwari A, Daniel E, Motihar A, Bhathiwal RS, Sharma D. Bivalirudin in venovenous extracorporeal membrane oxygenation. J Extra Corpor Technol 2014; 46 (1) 94-97
    PubMedGoogle Scholar
  • 63 Young G, Yonekawa KE, Nakagawa P, Nugent DJ. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 2004; 19 (5) 283-288
    CrossrefPubMedGoogle Scholar
  • 64 Ranucci M, Ballotta A, Kandil H , et al; Surgical and Clinical Outcome Research Group. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15 (6) R275
    CrossrefPubMedGoogle Scholar
  • 65 Al-Horani RA, Gailani D, Desai UR. Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants. Thromb Res 2015; 136 (2) 379-387
    CrossrefPubMedGoogle Scholar
  • 66 Annich GM, Meinhardt JP, Mowery KA , et al. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med 2000; 28 (4) 915-920
    CrossrefPubMedGoogle Scholar
  • 67 Batchelor MM, Reoma SL, Fleser PS , et al. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. J Med Chem 2003; 46 (24) 5153-5161
    CrossrefPubMedGoogle Scholar
  • 68 Skrzypchak AM, Lafayette NG, Bartlett RH , et al. Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation. Perfusion 2007; 22 (3) 193-200
    CrossrefPubMedGoogle Scholar
  • 69 Major TC, Brant DO, Burney CP , et al. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model. Biomaterials 2011; 32 (26) 5957-5969
    CrossrefPubMedGoogle Scholar
  • 70 Major TC, Brisbois EJ, Jones AM , et al. The effect of a polyurethane coating incorporating both a thrombin inhibitor and nitric oxide on hemocompatibility in extracorporeal circulation. Biomaterials 2014; 35 (26) 7271-7285
    CrossrefPubMedGoogle Scholar